3 Boston VCs Share Investment Themes for 2016

06 January, 2016

When it comes to healthcare—whether it is taking drugs, following a physical therapy routine, or just a plan to stay healthy—one of the biggest challenges is simply getting people to do what they’re supposed to do, and stick with it. “We’ve probably met with 100 companies around compliance,” says Callow. “We continue to believe it’s a very large opportunity.”

 
Related News
Xconomy’s EXOME Presents: What’s Hot in Boston Biotech
04.06.16
After an unprecedented multi-year bull run, biotech is facing headwinds once again. Drug companies have become a target in an election year, putting pricing strategies under a microscope. Valuations have tumbled, drying up a fertile ground for IPOs. Yet biotech innovation continues apace, particularly in Boston. Gene editing has taken the scientific world by storm, and may soon reach human clinical testing. New ways of harnessing the immune system to battle cancer are being unlocked. Investments in neuroscience, long a drug development minefield, have picked up. And local venture firms are armed with new funds to spend on startups. Read Full Release
Xconomy Forum: Robo Madness: The A.I. Explosion
03.31.16
Major advances are happening in robotics and the driving force behind it—artificial intelligence. Now companies of all sizes are using emerging A.I. technologies from deep learning to computer vision to natural language processing to build their businesses—and impact our daily lives. Think Google, Facebook, iRobot, and a whole new generation of startups: the technologies are already starting to transform retail, advertising, social media, transportation, connected homes, and other industries. Read Full Release